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Edited by Veli-Pekka LehtoAbstract Expression of CUB domain containing protein 1
(CDCP1) is upregulated in carcinoma cells. We quantitated
CDCP1 gene expression in matched normal colon and tumour
tissue and compared the level of expression to other genes upreg-
ulated in colorectal tumourigenesis. Furthermore, we show that
the CDCP1 gene generates two transcripts which are co-ex-
pressed in normal and matched tumour tissue as well as in the
majority of cell lines analysed. However, intracellular localisa-
tion studies revealed that only one of these transcripts encodes
a protein that is localised to the cell surface.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumour-associated antigens (TAAs) such as carcinoembry-
onic antigen (CEA) and epithelial cell adhesion molecule
(Ep-CAM) are well characterised proteins used as diagnostic
and prognostic markers in colorectal, breast and cervical can-
cers [1,2] as well as therapeutic targets for immunotherapy.
The CUB domain containing protein 1 (CDCP1) (also de-
scribed as SIMA135 and Trask) is a recently-described tumour
marker [3–5]. Sherl-Mostageer et al. ﬁrst described an mRNA
transcript encoding this protein using representational diﬀer-
ence analysis to identify diﬀerentially regulated genes in cancer
[5]. They described a putative transmembrane protein contain-
ing several CUB (complement protein subcomponents Clr/Cls,
Urchin embryonic growth factor and Bone morphogenic pro-
tein 1) domains. CUB domains are characterised by immuno-
globulin-like folds and are involved in protein:protein and
protein:carbohydrate interaction [6,7]. CDCP1 isoform 1 con-
tains at least 2 putative CUB domains [3–5] and has been re-
ported to have a role in cellular adhesion linked to cell
signalling via Src-family kinases and Protein Kinase Cd*Corresponding author. Fax: +44 113 343 3167.
E-mail address: g.e.blair@leeds.ac.uk (G.E. Blair).
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doi:10.1016/j.febslet.2007.02.025[4,8,9]. CDCP1 was found to be upregulated in human lung
and colon tumours as well as an erythroleukaemic cell line.
Further studies have reported that CDCP1 was expressed on
haematopoietic stem cells, mesenchymal stem cells, neuronal
progenitor cells [10,11], human epidermoid carcinoma cell lines
[3,8], breast and prostate carcinoma cell lines [4]. Ikeda et al.
have described a negative correlation of CDCP1 expression
with methylation of CpG sites within its promoter region
and suggest that expression of CDCP1 in cancer is attributable
to such epigenetic regulation [12].
The CDCP1 gene contains nine exons and the ﬁrst mRNA
transcript to be described (isoform 1) is approximately 6 kb
in length. The isoform 1 protein product is composed of 836
amino acids including a 29 residue signal sequence and a trans-
membrane domain which gives rise to a type I orientated inte-
gral membrane protein [3,5]. The observed Mr of CDCP1
isoform 1 protein ranges from 135 to 140 kDa [3,4,8,9] which
diﬀers from its calculated Mr (approximately 90 kDa) due to
extensive glycosylation. Northern blot analysis suggested the
presence of a shorter transcript and analysis of EST databases
identiﬁed a cDNA clone encoding a shorter transcript (acces-
sion number BC021099, IMAGE clone number 4590554) [13].
This suggested that a second CDCP1 transcript might be ex-
pressed in tumour cells. Here we show that the two CDCP1
transcripts are co-expressed in normal and tumour tissue.
To establish the importance of CDCP1 expression in colo-
rectal cancer relative to CEA and Ep-CAM, we have com-
pared their expression in colorectal tumour and matched
normal tissue. We further investigated the expression of
CDCP1 in a panel of colorectal and cervical cancer cell lines
and report for the ﬁrst time the expression of CDCP1 in
cervical carcinoma cell lines and the presence of the less-well
characterised isoform 2 transcript. Expression of CDCP1
cell-surface protein was found to vary between colorectal
carcinoma cell lines but this should not detract from its impor-
tance as a tumour marker as such variation was also observed
for both Ep-CAM and CEA.2. Materials and methods
2.1. Cell culture
A panel of colon carcinoma cell lines (SW480, HCT116, DLD-1,
WiDr, HRT18, HCT8, COLO 741, COLO 320, HT-29), cervical carci-
noma cell lines (CaSki, SiHa and HeLa), the lung carcinoma cell lineblished by Elsevier B.V. All rights reserved.
1138 S.E. Perry et al. / FEBS Letters 581 (2007) 1137–1142A549 and Chinese hamster ovary cells (CHO) were maintained as
monolayer cultures in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% (v/v) foetal calf serum, 100 U/mL penicillin
and 100 lg/mL streptomycin (Sigma–Aldrich).
2.2. RNA isolation, cDNA synthesis, quantitative and non-quantitative
PCR
RNA was isolated from 106 cells using TRIZol (Gibco Life Technol-
ogies) and treated with DNase (Promega) following the manufacturer’s
protocols. RNA isolated in this manner and RNA isolated from colon
tumour and matched normal tissue obtained commercially (Ambion)
was used to synthesise cDNA using Superscript II reverse transcriptase
(Invitrogen) according to the manufacturer’s protocols.
Quantitative real-time PCR was performed using the SYBR green
method using approximately 0.1 lg cDNA template, 1 lM of both for-
ward and reverse primers and SYBR green master mix (Applied Bio-
systems). The samples were prepared in 96 well plates and analysed
using a ABI PRISM 7900 HT (Applied Biosystems) following the man-
ufacturer’s protocols. Using Primer Express software (Applied Biosys-
tems) the following primers were designed: Forward (5 0-TGGTTC-
CACCCCAGAAATGT-30) and reverse (5 0-GATGATGCACAGA-
CGTTTTATAGATGA-30) primers to amplify a sequence within exon
3 of CDCP1 (present in both isoform 1 and 2); primers speciﬁc for
CEA (forward, 5 0-CTGGCCGCAATAATTCCATAG-3 0 and reverse,
5 0-CCAGCTGAGAGACCAGGAGAA-30) and primers speciﬁc for
Ep-CAM (forward, 5 0-CGTCAATGCCAGTGTACTTCAGTTG-30
and reverse, 5 0-TCCAGTAGGTTCTCACTGGCTCAG-30). Primers
designed to amplify the reference gene, GAPDH, (forward 5 0-
GAAGGTGAAGGTCGGAGTC-3 0 and reverse 5 0-GAAGATGGT-
GATGGGATTTC-3 0) [14] were also used.
Non-quantitative PCRwas performed on cDNA samples prepared as
described above. Forward (5 0-CTTCAACCTCTCCAACTGTG-3 0),
isoform 1-speciﬁc reverse (5 0-TGGTCTGTGCAGCTTATGGT-30)
and isoform 2-speciﬁc reverse (5 0-AGACTACCCAGGAAACAACG-
3 0) primers were designedmanually and all primers obtained fromEuro-
gentech. PCR was performed on a Techne GENIUS thermal cycler
using approximately 0.1 lg cDNA template, 10 pmol of each primer
and Mega Mix Blue master mix (Microzone). The products were ana-
lysed by 1.2% (w/v) agarose gel electrophoresis and images captured
using a VisiDoc-It Imaging System (UVP).
2.3. Plasmids
A pCDNA3.1 plasmid encoding C-terminal FLAG-tagged CDCP1
isoform 1 (pcDNA3.1-CDCP1iso1) was kindly provided by Stephen
Soltoﬀ, Beth Israel Deaconess Medical Center, Boston, USA [8].
CDCP1 isoform 2 was obtained from the IMAGE consortium (clone
4590554) and the coding sequence sub-cloned from the original pOTB7
vector into pcDNA3 (Clontech) (pcDNA3-CDCP1iso2) using EcoRI
and XhoI restriction sites.
2.4. Transfection and immunoﬂuorescence microscopy
Sub-conﬂuent CHO cells grown on glass cover slips were transfected
with the plasmid expression vectors pcDNA3.1-CDCP1iso1, pcDNA3-
CDCP1iso2 and empty pcDNA3 using Lipofectamine (Invitrogen) fol-CDCP1 Isoform 1 
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Fig. 1. Schematic representation of CDCP1 isoform 1 and isoform 2 transcri
UTR (open boxes) and transcribed regions (ﬁlled boxes). Isoform 1 mRNA
mRNA is approximately 1.4 kb in length and composed of 4 exons. (B) Predi
2 transcripts showing the signal peptide (hatched), CUB domains (dotted) an
composed of 836 amino acids and isoform 2 comprises 334 amino acids.lowing the manufacturer’s protocol. Twenty four hours post-transfec-
tion, the cells were washed twice with phosphate-buﬀered saline (PBS)
and ﬁxed using Acustain (Sigma–Aldrich). Cells were permeabilised (as
appropriate) with PBS containing 0.5% Triton X-100 (Sigma–Aldrich).
After extensive washing with PBS, the cells were blocked with PBS
containing 5% (v/v) normal goat serum (NGS) (Vector Laboratories)
and incubated for 1 h with the anti-CDCP1 mouse monoclonal anti-
body, CUB1 (obtained from MBL) diluted in PBS/5% (v/v) NGS to
a ﬁnal concentration of 1 lg/ml. The cells were washed with PBS
and incubated for a further hour with goat anti-mouse IgG F(ab 0)2
Fragment conjugated to Alexa Fluor 594 (Molecular Probes) diluted
in PBS/5% (v/v) NGS to a ﬁnal concentration of 2 lg/ml. The cells
were washed thoroughly, incubated with 0.5 lg/ml DAPI (Sigma–Al-
drich) and washed again before being mounted on to glass slides using
Vecta Shield mounting ﬂuid (Vector Laboratories). They were viewed
using an Axioplan 2 ﬂuorescence microscope and images captured
using the ApoTome (Zeiss), AxioCam MRm digital camera and Axio-
Vision 4.2 software.
2.5. Flow cytometry
One hundred thousand cells (105) were harvested by scraping adher-
ent cells from culture vessels using a rubber policeman. These were
blocked by incubation in PBS/10% (v/v) NGS and resuspended with
50 ll PBS, 10% (v/v) NGS containing 10 lg/ml mouse anti-CDCP1
monoclonal antibody, CUB1 (MBL) and incubated for 30 min at
4 C. The cells were washed twice in PBS and further incubated with
goat anti-mouse IgG conjugated to FITC (Sigma–Aldrich) diluted
1:50 in PBS/10% (v/v) NGS. Analysis was performed using a FAC-
SCalibur benchtop ﬂow cytometer and CellQuest software (Becton
Dickinson).3. Results and discussion
Since CDCP1 is known to be upregulated in tumour cells, we
ﬁrst set out to validate its application as a colorectal cancer
marker and potential therapeutic target by analysing its
expression in colon tissue compared to that of the well-charac-
terised tumour markers Ep-CAM and CEA. RNA samples
from colorectal tumour and matched normal tissue were sub-
jected to quantitative real time PCR using primers speciﬁc
for sequences within exon 3 of CDCP1 which is common to
both CDCP1 mRNA isoforms (Fig. 1). Comparison of
CDCP1, Ep-CAM and CEA expression in these samples dem-
onstrated equally signiﬁcant upregulation of these genes
(Fig. 2), conﬁrming the potential of CDCP1 as a novel tumour
marker.
The nucleotide sequence databases contain two CDCP1
transcripts; isoform 1 (accession number NM133974) and iso-
form 2 (accession number BC020199) suggesting alternativeCDCP1 Isoform 2 
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is approximately 6.4 kb in length and composed of 9 exons. Isoform 2
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Fig. 2. Expression of CDCP1, Ep-CAM and CEA in colorectal tissue. Quantitative real-time PCR was performed on cDNA synthesised from an
RNA sample obtained from human colon adenocarcinoma and matched normal tissue (Ambion). Primers speciﬁc to a region in exon 3, common to
both CDCP1 isoforms, were used to compare expression of CDCP1 transcripts to those of Ep-CAM and CEA relative to GAPDH control mRNA.
Values represent the mean of six independent experiments and error bars ± S.E. P < 0.05 between all tumour and matched normal samples for all
targets.
Fig. 3. Immunoﬂuorescence analysis of CDCP1 expression in trans-
fected cells. Immunoﬂuorescence microscopy of CHO cells transfected
with expression vectors coding for CDCP1 isoform 1 (A–F) and
isoform 2 (G–L), detergent-permeabilised (P) (A–C, G–I) to reveal
surface and intracellular CDCP1 and ﬁxed intact cells (NP) (D–F, J–L)
to reveal cell-surfaceCDCP1. Cells were treated with the anti-CDCP1
mouse monoclonal antibody CUB1 followed by Alexa 594-conjugated
anti-mouse IgG antibody fragment and analysed using the ApoTome
(Zeiss).
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gene allowed us to identify the origins of these isoforms
(Fig. 1A). The isoform 2 transcript is 1.4 kb in length and
the open reading frame continues from the exon 4 boundary
into the adjacent intron giving rise to a putative secreted pro-
tein of 343 amino acids with identity to the ﬁrst 341 residues of
isoform 1 including one putative CUB domain of isoform 1
but lacking the transmembrane domain (Fig. 1B). Its expres-
sion in tumour cells and its protein product have yet to be de-
scribed so we ﬁrst used immunoﬂuorescence microscopy to
characterise the intracellular localisation of the two isoforms.
CHO cells transfected with expression vectors coding for either
CDCP1 isoform 1 or 2 (Fig. 3) showed that only isoform 1 en-
codes a protein localised to the cell surface (Fig. 3E), consistent
with the presence of the transmembrane domain in this mole-
cule. In contrast, isoform 2 product could only be detected
intracellularly following permeabilisation (Fig. 3H). Cells
transfected with empty expression vector showed no staining
(data not shown). This demonstrates that the isoform 2 tran-
script encodes a protein that is not present at the surface of
cells. Interestingly, we did not detect a morphological change
similar to that observed by Bhatt et al. [4] in MDA-468TR cells
overexpressing CDCP1 isoform 1. This diﬀerence may be
attributable to the cell lines used.
We next analysed expression of the two transcripts in carci-
noma tissues and cell lines. We designed an isoform 1 reverse
primer speciﬁc to the sequence spanning the exon 4–5 bound-
ary and an isoform 2 reverse primer speciﬁc to a sequence
within the 3 0 UTR of the isoform 2 transcript. Using a com-
mon forward primer speciﬁc to a sequence within exon 3 of
CDCP1, PCR generated an isoform 1-speciﬁc 455 bp product
and an isoform 2-speciﬁc 294 bp product. Reverse transcrip-
tase (RT) PCR, using mRNA derived from CHO cells trans-
fected with expression vectors coding for either isoform 1 or
isoform 2 revealed that these primers were speciﬁc for the par-
ticular isoform (Fig. 4A) Samples where RT was omitted tocontrol for residual genomic DNA were negative (data not
shown). Using these primers, we were able to identify both iso-
Fig. 4. Analysis of CDCP1 mRNA expression in a panel of tumour cell lines. cDNA synthesised from RNA extracted from CHO cells transfected
with expression vectors (A), RNA obtained from human colon adenocarcinoma and matched normal tissue (Ambion) (B) and a panel of human
tumour cell lines (C and D) was used as the template for PCRs using primer sets speciﬁc for GAPDH (G), CDCP1 isoform 1 (1) and CDCP1 isoform
2 (2). The resulting products were resolved by agarose gel electrophoresis and the expected size of the GAPDH, CDCP1 isoform 1 and isoform 2
primer set products are indicated.
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(Fig. 4B) and cell lines (Fig. 4C) as well as cervical and lung
tumour cell lines (Fig. 4D). Interestingly, the presence of both
isoform 1 and isoform 2 transcripts was invariant and two of
the colorectal cell lines (Colo741 and Colo320) were found
to be negative for CDCP1 expression. This result was further
substantiated by analysis of CDCP1 surface expression by ﬂow
cytometry, a measure of CDCP1 isoform 1 protein expression
(Fig. 5A and B) and is in accordance with recently published
data [12]. Surface expression of CDCP1 on the cells tested var-
ied, however surface expression was detected on colorectal,
cervical and lung carcinoma cell lines with notably high levels
observed for HeLa cells. The colorectal cell lines Colo320 and
Colo741 expressed no signiﬁcant level of isoform 1 protein on
their cell surface as judged by ﬂow cytometry, consistent with
the lack of detectable CDCP1 transcripts in these cells. This
apparent lack of CDCP1 expression in these cell lines is most
notable and may distinguish between diﬀerent types of colorec-
tal cancer.
The major route taken by colorectal cells towards transfor-
mation is associated with chromosomal instability (CIN)
resulting in an aneuploid karyotype. A similar phenomenon
can be found in cervical and non-small cell carcinomas [15].
A smaller proportion of colorectal carcinomas present the
microsatellite instability (MSI) phenotype. These cells exhibit
genome-wide instability at the nucleotide level associated with
a near-diploid karyotype [16]. This phenotype has not been
associated with either cervical or non-small cell carcinoma cells
[17,18]. However, CDCP1 expression was not correlated with
cell lines described in the literature as exhibiting either CIN
or MSI phenotype [16,19,20]. Furthermore, and in accordance
with the ﬁndings of Hooper et al., CDCP1 expression did not
seem to be correlated with metastatic ability as the CDCP1-
negative Colo741 cells were derived from a pelvic wall metas-
tasis [3].
Interestingly, surface expression of Ep-CAM and CEA also
varied between cell lines (Fig. 5C and D). WIDR were found
to have exceptionally high surface levels of CEA (Fig. 5C)
which is in accordance with previous observations [21] andwe observed an apparent correlation of low CDCP1 with
Ep-CAM in both Colo741 and Colo320 and CEA in Colo320
(Fig. 5).
This leads us to propose that elevated expression of
CDCP1 could be a result but not a direct cause of transfor-
mation which does not preclude the possibility that it is a
marker of an as-yet undeﬁned sub-set of carcinomas. Further
studies investigating the expression of CDCP1 in primary
colorectal carcinoma cells in relation to progression using
the Dukes’s staging system are currently being pursued in
our laboratory.
The detection of CDCP1 isoform 2 transcripts in cell lines
expressing CDCP1 is an interesting ﬁnding. This transcript en-
codes a signal sequence and, in accordance with our observa-
tion that it is not retained at the plasma membrane, is likely
to encode a secreted soluble protein whose physiological role
remains unknown. Hooper et al. describe a membrane-shed
moiety of CDCP1 isoform 1 of approximately 110 kDa which
would be predicted to contain most of the extracellular domain
[3]. They also described strong immunohistochemical staining
in the goblet cells of normal colon crypts, lumen of glands
and in the glandular mucus of colon carcinoma, suggesting
the production of a soluble form of CDCP1. This may be
due to the membrane-shed extracellular domain of isoform 1
but it is also possible that these authors detected isoform 2.
It has also been reported that CDCP1 isoform 1 undergoes
proteolytic digestion by the serine protease MT-SP1 after ami-
no acid R369 and this cleavage is linked to intracellular signal-
ling pathways [4]. CDCP1 isoform 2 possesses the ﬁrst 341
residues of isoform 1 with an additional 2 amino acids at its
C-terminus. The proteolytically-released moiety of CDCP1
isoform 1 described by Bhatt et al. and isoform 2 would have
high identity and both possess the ﬁrst CUB domain of
CDCP1 [4]. Furthermore, Bu¨hring et al. reported that the
CUB1 antibody (which we found to recognise CDCP1 isoform
2) stimulated growth of erythroid colonies from CD34+ stem/
progenitor cells [10]. It is still unknown what physiological role
may be played by any of these three soluble forms of CDCP1,
but this warrants further investigation.
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Fig. 5. Analysis of CDCP1 isoform 1 protein product in a panel of tumour cell lines. A panel of cell lines was analysed by ﬂow cytometry using the
CUB1 mouse anti-CDCP1 antibody followed by FITC-conjugated anti-mouse IgG (A and B), FITC-conjugated anti-Ep-CAM (C) and mouse anti-
CEA antibody followed by FITC-conjugated anti-mouse IgG (D). The mean ﬂuorescence intensity (MFI) per cell of positive cells was determined
using a FACSCalibur benchtop ﬂow cytometer. Values represent the average MFI of three independent experiments, error bars represent ±1 S.E.
S.E. Perry et al. / FEBS Letters 581 (2007) 1137–1142 1141In conclusion, we show that the CDCP1 gene generates two
co-expressed transcripts, only one of which encodes a cell sur-
face molecule. Expression of CDCP1 in cell lines is similar to
that of the well documented tumour markers CEA and EP-
CAM and like these molecules, CDCP1 might prove to be a
useful therapeutic target.
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